The use of<unk> s is a decision based upon the risks and benefits of<unk> ion. The biggest risk of<unk> ion therapy is the increased risk of bleeding. In otherwise healthy people, the increased risk of bleeding is minimal, but those who have had recent surgery, cerebral aneurysms, and other conditions may have too great of risk of bleeding. Generally, the benefit of<unk> ion is prevention of or reduction of progression of a thromboembolic disease. Some indications for<unk>  therapy that are known to have benefit from therapy include: * Atrial fibrillation — commonly forms an atrial appendage clot * Coronary artery disease * Deep vein thrombosis — can lead to pulmonary embolism * Ischemic stroke * Hypercoagulable states (e.g., Factor V Leiden) — can lead to deep vein thrombosis * Mechanical heart valves * Myocardial infarction * Pulmonary embolism * Restenosis from stents * Cardiopulmonary bypass (or any other surgeries requiring temporary aortic occlusion) * Heart failure In these cases,<unk> ion therapy can prevent formation of dangerous clots or prevent growth of clots. The decision to begin therapeutic<unk> ion often involves the use of multiple bleeding risk predictable outcome tools as non-invasive pre-test stratifications due to the potential for bleeds while on blood thinning agents. Among these tools are HAS-BLED, ATRIA, HEMORR2HAGES, and CHA2DS2-VASc. The risk of bleeding using the aforementioned risk assessment tools must then be weighed against thrombotic risk in order to formally determine patient's overall benefit in starting<unk> ion therapy.
Anticoagulant
Decongestant
Anticonvulsant
Antipyretic
Cholagogue
Antiparasitic
Antipruritic
Abirritant